Skip to content
While it deliberates on whether to support the expansion of the international waiver of IP protections for COVID-19 therapeutics and diagnostics, the United States […]
Last chance for public hearing on the COVID IP waiver expansion Read More »
In recent years, Artificial Intelligence (AI) has boomed in healthcare. AI is helping scientists obtain relevant data, accurately predict diseases at early stages, and
I am BIO Podcast: How AI and biotech can ‘run evolution at hyperspeed’ Read More »
On Friday, March 10, 2023, the United States Food and Drug Administration (FDA) approved Acadia Pharmaceuticals’ drug for genetic Rett syndrome, the company announced
FDA approves Acadia’s DAYBUE for the treatment of Rett syndrome Read More »
Experts told a House subcommittee Wednesday that China’s government coordinates a strategy to steal U.S. intellectual property – and the waiver of COVID IP would
Congress shines a light on China’s strategy to steal U.S. IP Read More »
The third anniversary of the COVID-19 pandemic on March 11 may feel to some like a relief as we transition into a post-COVID era.
As the COVID pandemic turns 3, are we ready for the next one? Read More »
On March 8, 2023, during the first markup of health care bills this year, the Health Subcommittee of the House Energy and Commerce Committee
Legislation potentially banning QALYs due to discrimination is under review Read More »
The breakthrough Alzheimer’s drug LEQEMBI could receive traditional Food and Drug Administration (FDA) approval later this year after receiving Accelerated Approval in January. Developed
Alzheimer’s drug LEQEMBI granted Priority Review for traditional approval Read More »
After surviving five mass extinctions, horseshoe crab populations are under pressure—but a regulatory change allowing drug makers to use a synthetic alternative to crabs’
Horseshoe crab population can be spared with regulatory change Read More »
On March 2, 2023, the Biotechnology Innovation Organization (BIO) and 50 other national organizations announced the start of a coalition to advance trust in
BIO joins Coalition for Trust in Health & Science Read More »
Questions regarding the significant profits made by the 340B Drug Pricing Program were raised before the United States Senate Committee on Health, Education, Labor,
Fund tracing shows that a reform of 340B is long overdue Read More »
